Pulmatrix Profit Margin 2014-2021 | PULM
Current and historical gross margin, operating margin and net profit margin for Pulmatrix (PULM) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Pulmatrix net profit margin as of June 30, 2021 is -213.74%.
|Pulmatrix Annual Profit Margins
|Pulmatrix Quarterly Profit Margins
||Medical - Biomedical and Genetics
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.